Cancer Death Rate in Britain Falls Nearly a Third Since 1980s

Published: 09 March 2026. The English Chronicle Desk. The English Chronicle Online.

The cancer death rate in Britain has fallen by almost a third since the 1980s, research shows. This milestone highlights significant advances in prevention, early diagnosis, and life-saving treatments over the past four decades. According to Cancer Research UK (CRUK), approximately 247 people per 100,000 die from cancer each year, down from a peak of 355 per 100,000 in 1989. The figures reveal a steady decline, although cancer remains the leading cause of death in the UK.

Over the last decade, overall cancer mortality fell by 11%, reflecting improvements in targeted therapies and screening programmes. Deaths from ovarian cancer dropped by 19% between 2012-2014 and 2022-2024, stomach cancer by 34%, and lung cancer by 22%. Bowel cancer deaths decreased by 6%, breast cancer by 14%, cervical cancer by 11%, and leukaemia by 9%. Oesophageal cancer mortality also fell by 12% during this period, demonstrating broad progress across multiple cancer types.

Despite these reductions, some cancers showed rising mortality rates over the past ten years. Kidney cancer deaths increased by 5%, liver cancer by 14%, eye cancer by 26%, and gallbladder cancer by 29%. Other cancers, including thyroid, pancreatic, and melanoma, remained largely stable. These mixed trends highlight the ongoing need for innovation and investment in treatments.

Dr Sam Godfrey, science engagement lead at CRUK, said, “These figures represent decades of crucial scientific breakthroughs, from vaccines that prevent cancer to kinder, more targeted treatments. Thousands more people today can make memories, reach milestones, and spend precious time with their loved ones.”

The UK has been a global leader in cancer research, Godfrey noted, but he stressed that future progress is not guaranteed. “It’s essential that the government makes it easier and faster to set up clinical trials, as well as providing NHS staff with the time and space to carry out life-saving research.”

Last year, the Guardian reported that British cancer patients were being denied access to life-saving drugs, and trials for revolutionary treatments were being hampered by post-Brexit bureaucracy. The UK’s departure from the EU has affected doctors’ ability to deliver new drugs through international clinical trials, according to the most comprehensive report of its kind.

CRUK attributed falling cancer deaths to multiple factors, including smoking bans and the widespread adoption of screening programmes for breast, bowel, and cervical cancers. Cervical cancer mortality has dropped by 75% since the 1970s, largely due to the NHS cervical screening programme. The introduction of the human papillomavirus (HPV) vaccine in 2008 has also been pivotal, with around 6.5 million people in the UK vaccinated to date, further reducing cervical cancer risk.

Prostate cancer deaths also fell by 11% over the last decade, helped by improved treatments. The drug Abiraterone, developed by CRUK scientists, blocks testosterone from fuelling prostate cancer, offering patients a more effective therapy option.

Nevertheless, the rising and ageing population means more people are being diagnosed with cancer, with one new case every 75 seconds in the UK. Consequently, the absolute number of cancer deaths continues to rise, even as age-standardised mortality falls. This dual trend underscores the scale of the ongoing public health challenge.

A Guardian analysis last year found that three-quarters of NHS hospital trusts are failing cancer patients, prompting medical experts to declare a national emergency. In response, the government pledged £2 billion last month to transform cancer services, promising faster diagnoses, quicker treatment, and additional support to help patients live well.

Some NHS cancer performance targets have been missed since 2015. Under the current national cancer plan, ministers have committed to meeting all three waiting time standards by 2029, reflecting a long-term effort to improve patient care and outcomes.

These achievements demonstrate the transformative power of science, early detection, and public health measures in reducing cancer mortality. While challenges remain, including rising cases in certain cancer types, the UK’s sustained research and clinical efforts offer hope for continued progress in combating the disease.

Check our latest news